Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Pazianas

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
JBMR Plus|August 9, 2021
NE-58025: A bisphosphonate with a low hydroxyapatite binding affinityMichael Pazianas
Calcified Tissue International|December 27, 2022
RE: One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational StudyMichael Pazianas
Arthritis Care & Research|June 11, 2010
Association between the use of serotonin receptor 2A-blocking antidepressants and joint disorders: comment on the article by Kling et alMichael Pazianas
Journal of the National Cancer Institute|December 30, 2010
Osteonecrosis of the jaw and the role of macrophagesMichael Pazianas
JAMA Internal Medicine|January 16, 2013
Are bisphosphonates associated with an increased risk of atypical femoral fractures as a class?Michael Pazianas
Nephrology (Carlton, Vic.)|January 31, 2019
FGF-23 in untreated nephrotic syndrome and effects of the renin-angiotensin-aldosterone systemMichael Pazianas
Postgraduate Medical Journal|January 6, 2017
Oestrogens and ageing from the skeletal perspectiveMichael Pazianas
Postgraduate Medical Journal|August 19, 2019
Bones, heart and the new anabolic agent romosozumabMichael Pazianas
The Journal of Clinical Endocrinology and Metabolism|April 17, 2019
Letter to the Editor: "Dietary Calcium Intake and Bone Loss Over 6 Years in Osteopenic Postmenopausal Women"Michael Pazianas
Annals of the New York Academy of Sciences|March 26, 2018
Effectiveness of calcium and vitamin D supplementation in osteoporosisMichael Pazianas
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
JBMR Plus|August 9, 2021
NE-58025: A bisphosphonate with a low hydroxyapatite binding affinityMichael Pazianas
Calcified Tissue International|December 27, 2022
RE: One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational StudyMichael Pazianas
Arthritis Care & Research|June 11, 2010
Association between the use of serotonin receptor 2A-blocking antidepressants and joint disorders: comment on the article by Kling et alMichael Pazianas
Journal of the National Cancer Institute|December 30, 2010
Osteonecrosis of the jaw and the role of macrophagesMichael Pazianas
JAMA Internal Medicine|January 16, 2013
Are bisphosphonates associated with an increased risk of atypical femoral fractures as a class?Michael Pazianas
Nephrology (Carlton, Vic.)|January 31, 2019
FGF-23 in untreated nephrotic syndrome and effects of the renin-angiotensin-aldosterone systemMichael Pazianas
Postgraduate Medical Journal|January 6, 2017
Oestrogens and ageing from the skeletal perspectiveMichael Pazianas
Postgraduate Medical Journal|August 19, 2019
Bones, heart and the new anabolic agent romosozumabMichael Pazianas
The Journal of Clinical Endocrinology and Metabolism|April 17, 2019
Letter to the Editor: "Dietary Calcium Intake and Bone Loss Over 6 Years in Osteopenic Postmenopausal Women"Michael Pazianas
Annals of the New York Academy of Sciences|March 26, 2018
Effectiveness of calcium and vitamin D supplementation in osteoporosisMichael Pazianas
Pageof 6